For instance, the therapeutic potential of type I and type II IFN combination therapy is revealed in a new formulation of IFNs (HeberFERON) which resulted in a higher number of complete responses for patients with basal cell carcinoma and prolongation of survival for patients with glioblastoma and renal cell carcinoma [223]. This evidence concerns the gene SGCG and glioblastoma.